Navigation Links
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Date:9/15/2008

y: Tilmann M Brotz, Ph.D., Vice President of Pre-Clinical

Research and Development, VIA Pharmaceuticals

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets ... of the "Global Gynecological Devices Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... wide categories based on their operations. These ... different gynecological conditions that affect the female ...
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Inc. (NASDAQ: DCTH ) announced today that management ... Conference on Tuesday, August 16, 2011 at 2:25 P.M. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. Delcath will offer a live audio webcast of ...
... 10, 2011 Leading events organizers UBM Canon ... (LSE: UBM), today announced a virtual conference event which will examine ... chain, counterfeit drugs. Titled ,Pharmaceutical Track & Trace Authentication: The Fight ... from 6:00 to 14:00 New York time, 12:00 to 20:00 Paris ...
Cached Medicine Technology:Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 3UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 2UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 3
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- The U.S. Food and Drug ... Thursday. Trulicity is part of a class of once-a-week injectable ... type 2 diabetes. "Trulicity is a new treatment ... treatment regimens to control blood sugar levels in the overall ... of the FDA,s Office of Drug Evaluation II, said in ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- More states are ... medication epinephrine to use for any child having a ... treatment for "anaphylaxis," an allergic reaction that can lead ... blood pressure and even death. In people ... or tree nuts, insect venom or certain drugs, anaphylaxis ...
(Date:9/19/2014)... 19, 2014 Top 10 Best ... announced that HostGator.com, GoDaddy and Bluehost are among ... companies are the most recommended suppliers for webmasters ... to buy high quality Linux hosting (including VPS ... is one of many top hosting companies that ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:A better way to track emerging cell therapies using MRIs 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2
... REMIND LAWMAKERS CALIFORNIA PREMIUMS ARE 17 PERCENT ... ... At the Assembly,Health Committee,s hearing on Governor Arnold Schwarzenegger,s health ... National Association of Insurance and Financial Advisors-California,(NAIFA-California) urged lawmakers to ...
... 31 Conseco, Inc. (NYSE:,CNO) today reported results for ... reflect a number of significant events, as,progress on our ... increasingly evident," CEO Jim Prieur said. "We saw continued,strong ... businesses, while,Conseco Insurance Group, even with a decline in ...
... Effective ... Alternatives, LOS ... thinking about health and medicine over the past few years as ... As concerns grow regarding conventional, over-the-counter,medicine, Hyland,s homeopathic medicines offer a ...
... Dr. James M. Farrell, a,doctor of chiropractic practicing ... Chiropractic Association (CCA). He was nominated,and chosen by his ... the CCA since 1992, Dr. Farrell has been extremely ... a committee chair, board member,and executive board member prior ...
... Today researchers report a newly identified genetic ... cancer in African American men. This study, which ... prostate cancer in high-risk populations, is published online in ... cancer is the second leading cause of cancer death ...
... feline DNA could help humans, too, scientists say , WEDNESDAY, ... of the domestic cat ( Felis catus ), an advance ... pets and provide an excellent model for human disease. , ... traced back several generations to Sweden, was the subject of ...
Cached Medicine News:Health News:Health Insurance Agents Warn Against Imposing a 'Health Care Reform' Tax in California 2Health News:Health Insurance Agents Warn Against Imposing a 'Health Care Reform' Tax in California 3Health News:Conseco Reports Third Quarter Results 2Health News:Conseco Reports Third Quarter Results 3Health News:Conseco Reports Third Quarter Results 4Health News:Conseco Reports Third Quarter Results 5Health News:Conseco Reports Third Quarter Results 6Health News:Conseco Reports Third Quarter Results 7Health News:Conseco Reports Third Quarter Results 8Health News:Conseco Reports Third Quarter Results 9Health News:Conseco Reports Third Quarter Results 10Health News:Conseco Reports Third Quarter Results 11Health News:Conseco Reports Third Quarter Results 12Health News:Conseco Reports Third Quarter Results 13Health News:Conseco Reports Third Quarter Results 14Health News:Conseco Reports Third Quarter Results 15Health News:Conseco Reports Third Quarter Results 16Health News:Conseco Reports Third Quarter Results 17Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:Golden Doctor of Chiropractic Elected President of the Colorado Chiropractic Association 2Health News:Scientists discover genetic variant associated with prostate cancer in African Americans 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e...
The Livewire cannulator offers improved access to the coronary sinus by combining the ergonomic Livewire steering mechanism with numerous specialized features....
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
Medicine Products: